FCER1G and Alzheimer disease: To confirm selectivity toward Aβ we used the FcRγ CAR (Fig. 1B) as base and replaced the scFv derived from aducanumab (the first anti-amyloid antibody to receive FDA approval for treatment of AD) with that of two other amyloid-targeting antibodies (lecanemab and donanemab), as well as an α-synuclein-targeting scFv (prasinezumab) (Fig. 2A).